Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
about
Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests.Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.Pharmacogenomics in early-phase clinical developmentPharmacokinetic behavior presents drug therapy challenges.
P2860
Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacogenomics in early-phas ...... here a sweet spot in phase II?
@en
Pharmacogenomics in early-phas ...... here a sweet spot in phase II?
@nl
type
label
Pharmacogenomics in early-phas ...... here a sweet spot in phase II?
@en
Pharmacogenomics in early-phas ...... here a sweet spot in phase II?
@nl
prefLabel
Pharmacogenomics in early-phas ...... here a sweet spot in phase II?
@en
Pharmacogenomics in early-phas ...... here a sweet spot in phase II?
@nl
P2860
P1476
Pharmacogenomics in early-phas ...... here a sweet spot in phase II?
@en
P2093
Peter H O'Donnell
Walter M Stadler
P2860
P304
P356
10.1158/1078-0432.CCR-11-2445
P407
P577
2012-03-16T00:00:00Z